Who
Shao-Lee Lin
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Cue Biopharma; Director, Surrozen; Chief Executive Officer, Acelyrin; Director, Third Harmonic Bio; Director, Principia Biopharma; EVP, Head of R&D and CSO, Horizon Therapeutics Public Ltd Co.
In numbers
- Trades disclosed
- 94
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $3.8M
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 4 Jan 2018
- Last trade
- 12 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 14 Oct 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $275K10,000 at $27.50 | filing |
| 12 Oct 2026filed 14 Oct 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $30K1,087 at $28.05 | filing |
| 13 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $147K5,423 at $27.19 | filing |
| 13 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $67K2,375 at $28.11 | filing |
| 13 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $308K10,460 at $29.48 | filing |
| 13 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $147K5,423 at $27.19 | filing |
| 13 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $67K2,375 at $28.11 | filing |
| 13 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $308K10,460 at $29.48 | filing |
| 12 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Code M | —109,179 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $924K34,225 at $26.99 | filing |
| 12 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $160K5,775 at $27.75 | filing |
| 12 Aug 2026filed 14 Aug 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —109,179 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —109,179 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Code M | —109,179 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $924K34,225 at $26.99 | filing |
| 12 Aug 2026filed 14 Aug 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Sold | $160K5,775 at $27.75 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Code A | —327,537 at $0.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —327,537 at $0.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —327,537 at $0.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Code A | —327,537 at $0.00 | filing |
News
Cue Biopharma (NASDAQ:CUE) Stock: Insider Michael Vincent Meluzio Sells 1,144 SharesCUE · dailypolitical.com · 15 Oct 2026Cue Biopharma (NASDAQ:CUE) Insider Sells $51,724.20 in StockCUE · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Shao-Lee Lin; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.